{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-014287","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.268362+00:00","generated_at":"2026-05-16T02:59:56.608700+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Rezolute Q2 net loss $22.8M; Phase 3 congenital HI study misses primary endpoint","bullets":["Net loss $22.8M vs $15.7M YoY; R&D $14.3M, G&A $9.9M; cash $132.9M down from $167.9M.","Phase 3 sunRIZE study of ersodetug for congenital HI did not meet primary or key secondary endpoints.","Reduction in hypoglycemia by CGM was statistically significant at Week 16 but not at Week 24 endpoint.","FDA meeting planned under Breakthrough Therapy designation before end of Q1 to discuss next steps.","Enrollment ongoing for tumor HI Phase 3 upLIFT study; topline results expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-014287","json":"https://secwatch.observer/filing/0001104659-26-014287.json","markdown":"https://secwatch.observer/filing/0001104659-26-014287.md","text":"https://secwatch.observer/filing/0001104659-26-014287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926014287/0001104659-26-014287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926014287/tm265567d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:59:56.608700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}